ARCT
ARCT
NASDAQ · Biotechnology

Arcturus Therapeutics Holdin

$6.72
-0.10 (-1.47%)
As of Jul 4, 2:08 AM ET ·
Financial Highlights (FY 2026)
Revenue
92.23M
Net Income
-73,964,644
Gross Margin
Profit Margin
-80.2%
Rev Growth
-26.4%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 42.6% 42.6%
Operating Margin -93.0% -83.7% -13.7% -14.9%
Profit Margin -80.2% -76.2% -16.2% -15.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 92.23M 125.37M 31.39M 23.67M
Gross Profit 13.39M 10.09M
Operating Income -85,740,109 -104,887,995 -4,296,176 -3,517,635
Net Income -73,964,644 -90,482,777 -5,088,256 -3,711,629
Gross Margin 42.6% 42.6%
Operating Margin -93.0% -83.7% -13.7% -14.9%
Profit Margin -80.2% -76.2% -16.2% -15.7%
Rev Growth -26.4% -26.4% +5.3% +9.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 42.41M 50.91M
Total Equity 148.93M 147.38M
D/E Ratio 0.28 0.35
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -82,343,055 -106,328,533 -7,015,778 -5,079,230
Free Cash Flow -5,929,972 -4,352,810